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Abstract
Objective To evaluate effectiveness and safety of titrated
oral misoprostol solution (OMS) in comparison with
vaginal dinoprostone for cervix ripening and labor induc-
tion in term pregnant women.
Methods A multicenter randomized controlled trial of
women with term singleton pregnancy with indications for
labor induction; 481 participants were allocated to receive
titrated OMS with different doses by hourly administration
according to the procedure or insert vaginal dinoprostone
for cervix ripening and labor induction to compare mater-
nal outcomes including indication of labor induction, mode
of outcome of delivery, maternal morbidity, and neonatal
outcomes between two groups for evaluating the efficacy
and safety of titrated oral misoprostol induction.
Result Proportion of delivery within 12 h of titrated oral
misoprostol is significantly less than vaginal dinoprostone
(p = 0.03), but no difference of total vaginal delivery rate
(p = 0.93); the mean time of first treatment to vaginal
delivery was longer in OMS group (21.3 ± 14.5 h) com-
pared with the vaginal dinoprostone group (15.7 ± 9.6 h).
Although the proportion of cesarean section between the
two groups showed no statistically significant difference,
OMS group showed significantly lower frequency of uter-
ine hyperstimulation, hypertonus, partus precipitatus and
non-reassuring fetal heart rate than dinoprostone group.
Neonatal outcomes were similar evaluating from Apgar
score and NICU admission. Our study also showed that
labor induction of women with cervix Bishop score B3
needed increased dosage of misoprostol solution.
Conclusion Titrated OMS is as effective as vaginal
dinoprostone in labor induction for term pregnant women,
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Background
Induction of labor is a commonly practiced obstetric
intervention designed to artificially initiate the process of
effacement of cervix, dilatation and eventually delivery of
baby. Adopting safe and effective methods of labor
induction at appropriate gestation age can greatly decrease
complications and morbidity of pregnancy and fetus. In
recent years, the rate of induction presents gradually
increasing tendency, and the incidence for labor induction
dramatically varies 8–44 % [1–3]. Therefore, looking for
induction methods with safety, efficacy, feasibility, low
cost, and patient preferences, for a long time, is a pursuit of
the goal of all obstetric providers.
Recently, many studies reported oral misoprostol for
labor induction with different doses and interval times; at
the same time, respectively compared with other induction
methods including vaginal insert misoprostol, oxytocin,
Foley catheter induction, oxytocin associated Foley
catheter and vaginal insert Dinoprostone. The target of all
these studies is to evaluate the safety and effectiveness of
oral misoprostol for labor induction. According to these
study results, we propose the concept that misoprostol will
be a new promising agent for cervical ripening and
induction of labor, but ideal dose, route and administration
frequency are still needed for investigation.
Misoprostol, a synthetic prostaglandin E1 analog, can be
administered orally, sublingually, buccally, intra-vaginally,
or rectally and is used for both cervical ripening and labor
induction. The World Health Organization recommends a
fixed oral misoprostol dose of 25 mg every 2 h for labor
induction based on moderate-quality evidence and strong
recommendation [4]. However, trials continue in efforts to
identify the optimum treatment regimen.
On the basis of the misoprostol pharmacokinetics, this
medicine shows the characteristics of rapid oral absorption,
its active metabolites of misoprostol acid in plasma reach
peak value after 15 min of oral administration, and its
mean tmax concentration is 0.309 lg/L. Its half-life is
20–40 min following oral administration, followed by a
rapid decline to low levels during the period of 120 min,
thereafter with a more gradual decline, and no drug accu-
mulation phenomenon. According to its pharmacokinetics
property, we designed the administration procedure of
hourly titrated oral misoprostol dosing and gradually
increasing dosage, compared with 2 h dosing; this proce-
dure may make drug serum level more steady with better
efficacy, and at last improve clinical induction outcome.
Materials and methods
Design
This trial was a multicenter, open-label, randomized con-
trolled trial. The study was performed within four obstetric
centers; participating hospitals can be district, teaching or
academic hospitals. Before entry into the study, women
were informed about the aims, methods, reasonably antic-
ipated benefits and potential hazards of the study. Prior to
interview, informed consents had been taken from every
respondent. Patients who met the selection criteria were
explained about advantages and disadvantages of the pro-
cedure. Among them, those who provided their informed
consents were interviewed and recruited in the study. They
were informed that their participation would been volun-
tary and may withdraw consent for participation at any
time during the study.
Inclusion criteria
All the women must be singleton pregnancies with
occipital presentation, nullipara, gestational age is at
least 36 weeks, Bishop score less than six, no vaginal
delivery contraindication, e.g. cephalopelvic dispropor-
tion, mal-presentation, fetal compromise, no reassuring
fetal heart rate pattern, previous scar and antepartum
haemorrhage.
Exclusion criteria
Women with any contraindication to induction and vagina
delivery, allergic to prostaglandin, and with complication
of glaucoma, asthma and allergic colitis, woman with
heart, liver, renal and adrenal cortex insufficiency.
Multicenter randomized control design
This multicenter randomized controlled trial was con-
ducted from January to October in 2014 at four gyneco-
logic and obstetric departments (including Obstetric
Department of Affiliated Guangren Hospital of Xi’an
Jiaotong University; Obstetric Department of First Affili-
ated Hospital of Medical College of Xi’an Jiaotong
University in China; Obstetric Department of Maternal and
Child Care Service Center of Northwest; Obstetric
Department of Shannxi Province People Hospital). On
enrollment, an opaque envelope corresponding to the par-
ticipant’s enrollment number was opened assigning women
to either oral misoprostol or vaginal insert dinoprostone
group determined by a computer-generated randomization
sequence.
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Methods of administration and evaluation
Based on the WHO labor induction recommendation, and
for the purpose of achieving precise oral misoprostol
dosage, we pulverized one misoprostol tablet (200 lg),
dissolved into 200 ml water, then one misoprostol tablet
(200 lg) was made into 1 lg/ml concentration oral miso-
prostol solution (OMS), and preserved at room temperature
for 24 h.
All the women enrolled into OMS group were given
misoprostol solution according to the procedure (Fig. 1)
and ceased procedure at any time when reached one of the
following criteria: including regular uterine contractions
every 3–5 min and lasting 60 s or more; dilatation of cer-
vix reached 2.0 cm; emerging membrane rupture; uterine
tachysystole; uterine hyperstimulation as tachysystolic,
non-reassuring fetal heart rate. The whole procedure spent
10.5 h, when woman ends the first procedure with no signs
of regular uterine contraction, after 6 h interval, we would
begun second cycles procedure, in second procedure, the
criteria of ceasing procedure is as same as previous norms.
The vaginal insert dinoprostone was given according to
the drug protocol. Dinoprostone should be removed from
the freezer in direct connection with the insertion, and be
inserted high into the posterior vaginal fornix using only
small amount of water soluble lubricants to aid insertion.
After dinoprostone has been inserted, the withdrawal tap
may be cut with scissors ensuring there is sufficient tap
outside the vagina to allow removal. The norms of termi-
nating drug administration were as same as OMS group.
When participants began the process of labor induction,
abdominal palpation uterine contraction and electric mon-
itoring would be taken to evaluate uterine contraction, fetal
heart-rate every hour, and vaginal exam to know the
dilatation of cervix every 1–2 h.
Outcomes measure
General situation of participants: including age, gestational
age, body mass index (BMI). Indication of labor induction:
premature rupture of membrane (PROM), oligohydram-
nios, post-term gestation, pre-eclampsia, gestational dia-
betes mellitus (GDM) controlled without insulin, and other
reasons. Mode and outcome of delivery: including mode of
delivery such as spontaneous delivery, vaginal operative
delivery or cesarean section, and the reason for operative
delivery and cesarean section; Induction to delivery time:
less than 12 h delivery, 12–24 h delivery and 24–48 h
delivery; Cervix Bishop score; total oral misoprostol
dosage; oxytocin use situation; requirement of analgetics;
pertus precipitatus (defined as the total time of labor stage
less than 3 h); reasons of cesarean section and operative
delivery. Maternal morbidity: postpartum blood transfusion
and number of packed cell, Tachysystole (defined as more
than five contractions in 10 min); hyperstimulation (de-
fined as tachysystole with FHR changes); uterine hyper-
tonus (defined as a contraction lasting longer than 2 min
with FHR changes); Uterine rupture (occurrence of clinical
symptoms include abdominal pain, abnormal fetal heart
rate pattern, acute loss of contractions and vaginal blood
loss) leading to an emergency cesarean delivery, at which
the presumed diagnosis of uterine rupture was confirmed;
or peripartum hysterectomy or laparotomy for uterine
rupture after vaginal birth); Maternal infection during labor
(defined as fever, i.e. temperature C37.8 C, or fetal
tachycardia and start of antibiotics); maternal infection
within 1 week postpartum (defined as fever, i.e. tempera-
ture C37.8 C, and start of antibiotics); start of intravenous
antibiotics; endo (myo)metritis or urinary tract infection
within 1 week postpartum (proven positive vaginal/urine
culture); other medication used during labor such as
tocolytics. Neonatal parameters consisting of: fetal tachy-
cardia (sustained fetal heart rate above 160 beats per
minute), fetal distress; weight at birth; meconium-stained
liquor; Apgar scores\7 at 1, 5, and 10 min; admission to
the neonatal ward/NICU and its reason (suspected infec-
tion, infection proven by positive culture, other reason
admission to medium or intensive care).
Statistical analysis
All data were analyzed by statistics software SPSS 19.0.
Results were given as mean ± SD or percentage, time
intervals were analyzed with ANOVA test, other data were
analyzed with v2 for qualitative and Student’s t test for
quantitative variables. All tests were two-sided, p\ 0.05
was considered statistically significant.
Results
A total of 481 women met the inclusion criteria and
approached regarding study participation, 35 women
declined, of whom 228 women were randomized to OMS
group and 218 women to vaginal dinoprostone group. 35
participants did not receive the assigned drug, 16 women in
the OMS group and 19 women in vaginal dinoprostone
group. Reasons for not receiving the study drug mainly
included the following causes: initiating spontaneous reg-
ular uterine contraction, non-reassuring FHR, and refusal
of study drug (Fig. 2).
There were no differences in maternal age, gestational
age and body weight index between OMS and vagina
dinoprostone groups (Table 1). We also compared the
labor induction indication between two groups, showed no
difference of indication in oligohydramnios, posterm
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First  20ug 
Second  20ug 
  30ug administrated three times, at 1h interval 
  1h interval 
  1h interval 
40ug administrated one time, at 1.5h interval  
  1h interval 
 Test dose 
50ug administrated one time, at 2h interval  
  1.5h interval 
60ug administrated two times, at 2h interval  
  2h interval 
Ceased administration even if no regular uterine constraction 
  2h interval 
 Labor 
induction dose 
Note: ceased procedure at any time when reached one criteria of following norm, including regular 
uterine contractions every 3-5 minutes and lasting 60 seconds or more; dilatation of cervix reached 
2.0cm; emerging membrane rupture, uterine tachysystole, uterine hyperstimulation as tachysystolic, 
non-reassuring fetal heart rate.  
Uterine tachysystole was defined as more than 5 contractions in a 10 minute period without fetal heart 
rate changes and uterine hyperstimulation as tachysystolic uterine contractions associated with 
non-reassuring fetal heart rate pattern. Non-reassuring fetal heart rate was defined as an abnormal fetal 
heart rate on electronic monitoring such as more than three continuous late deceleration, frequent 
emerging serious variable deceleration. 
Fig. 1 Flow diagram of process of hourly adminstration titrated oral misoprostol solution and ceased procedure criteria
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gestation, gestational diabetes, preterm rupture of mem-
brane, pre-eclampsia, and fetal growth restriction
(Table 2).
Proportion of vaginal delivery between OMS (182/212,
85.8 %) and vaginal dinoprostone (163/199, 81.9 %)
showed no difference. We further analyzed from the
interval of time, within 12 h the proportion of vaginal
delivery in OMS was lower than dinoprostone group with
significant difference (p = 0.03), but during 24–48 h the
percentage of vaginal delivery was obviously higher than
dinoprostone (p = 0.04), and during 12–24 h delivery
proportion was similar between two groups (p = 0.89);
Trial profile





Randomized to titrated oral misoprostol
N=228
Randomized to vaginal dinoprostone
N=218
Received study drug   
n=212
Received study drug  
n=199
Did not received study drug: n=16
Initiate spontaneous regular uterine 
contraction before administrating drug: 
(n=9); Abnormal fetal heart rate 
monitoring: (n=5); Refused study drug: 
(n=2)
Did not received study drug: n=19
Initiate spontaneous regular uterine 
contraction before administrating 
drug: (n=8); Abnormal fetal heart rate 
monitoring: (n=6); Refused study 
drug: (n=5)
Analyzed n=212 Analyzed  n=199
Fig. 2 Procedures for the selection and follow-up of participants
Table 1 General condition of
study participants
Oral misoprostol (n = 212) Dinoprostone (n = 199) p value
Maternal age (years) 27.8 ± 4.8 (18–39) 28.3 ± 5.6 (18–35) 0.84
Gestational age (weeks) 39.5 ± 6.2 (36–42) 38.8 ± 7.1 (36–42) 0.98
BMI (Kg/m2) 25.3 ± 8.7 (18.9–33.5) 26.1 ± 8.2 (18.5–32.8) 0.89
Data are mean ± SD (range)
BMI body mass index
Table 2 Indication of labor
induction
Oral misoprostol (n = 212) Dinoprostone (n = 199) p value
Oligohydramnios 127 (56.9) 117 (58.7) 0.92
Post term-gestation 32 (15.1) 36 (18.0) 0.87
GDM 13 (6.1) 11 (5.5) 0.72
PROM 19 (8.9) 15 (7.5) 0.82
Pre-eclampsia 12 (5.6) 10 (5.0) 0.90
FGR 6 (2.8) 6 (3.0) 0.91
Other 3 (1.4) 4 (2.0) 0.73
Data are number (percentage)
GDM gestational diabetes mellitus, PROM premature rupture of membrane, FGR fetal growth restriction
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however, the mean time of first treatment to vaginal
delivery was significantly longer in OMS group
(21.3 ± 14.5 h) compared with the vaginal dinoprostone
group (15.7 ± 9.6 h). Proportion of cesarean section in
vaginal dinoprostone (36/199, 18.0 %) was a little higher
than OMS (30/212, 14.2 %), but statistically no signifi-
cance, analyzing the indication of cesarean section, the
dinoprostone group showed higher fetal distress, but the
difference without statistically significant, and proportions
of delivery process block were similar between groups. The
proportion of total vaginal operative delivery showed no
significant difference between the two groups, and causes
of vaginal operative delivery (forceps and vacuum extrac-
tor delivery) mainly include uterine atony, fetal distress
and delivery process block, proportion of three main causes
of vaginal operative delivery were similar. Compared other
respects include using oxytocin and requirement of anal-
getics showed no difference between groups. Proportion of
partus precipitatus in vaginal dinoprostone (9/163, 5.5 %)
was higher than oral misoprostol (5/182, 2.7 %) (Table 3).
Based on women cervix Bishop score, we divided into
two subgroups, respectively, B3 and 4–6. We found that
proportions of successful induction were similar between
groups, however, Bishop score less than 3 or 4–6, but
women with Bishop score B3 in oral misoprostol group
administered more misoprostol solution dose. The mean
dosage of oral misoprostol solution is 180 ± 120 lg, and
further stratified by cervix Bishop score, the mean dosage
of misoprostol 435 ± 124 lg in the Bishop score B3, and
152 ± 95 lg in the Bishop score 4–6 subgroup. Duration
time of first treatment to vaginal delivery was longer than
Bishop score 4–6 subgroup; 51 women gave birth during
24–48 h. We also compared the frequency of maternal
adverse events between groups, the overall uterine
tachysystole was not different between the two groups; 18
women in vaginal dinoprostone group had hyperstimula-
tion, its frequency is significantly higher than oral miso-
prostol group (p = 0.03). Five women in oral misoprostol
and 16 women in vaginal dinoprostone presented uterine
hypertonus with significantly difference (p = 0.03). 6
women in OMS and 17 in dinoprostone group needed
tocolytics to inhibit uterine hyperstimulation, tachysystole
and hypertonus, the result showed significantly difference
(p = 0.04). The proportion of membrane rupture phe-
nomenon in OMS (59/212, 27.8 %) is higher than vaginal
dinoprostone (26/199, 13.1 %). Proportion of postpartum
heamorrhage and intravenous antibiotics was similar
between the groups, and maternal other adverse event
including fever, shivering, nausea and vomiting also pre-
sent no difference (Table 4).
Neonatal outcomes are shown in Table 5, neonatal
Apgar scores B7 at the interval of 1, 5 and 10 min were no
different, and the proportions of Meconium-stained liquor
and neonate NICU admission were also similar, but non-







Delivered vaginally 182/212 (85.8) 163/199 (81.9) 0.93
\12 h 39/182 (21.4) 65/163 (40.1) 0.03
During 12–24 h 79/182 (43.4) 66/163 (40.4) 0.89
During 24–48 h 58/182 (31.9) 28/163 (17.2) 0.04
First treatment to vaginal delivery,
mean h
21.3 ± 14.5 15.7 ± 9.6 0.04
Bishop score
B 3 69/182 (37.9) 57/163 (34.9) 0.32
4–6 113/182 (62.1) 106/163 (65.0) 0.78
Cesarean section 30/212 (14.2) 36/199 (18.0) 0.34
Fetal distress 7/30 (23.3) 10/36 (27.8) 0.44
Delivery process block 23/30 (76.7) 26/36 (72.2) 0.86
Vaginal operative delivery 22/182 (12.1) 29/163 (17.8) 0.50
Uterine atony 8/22 (36.4) 9/29 (31.0) 0.80
Fetal distress 8/22 (36.4) 12/29 (41.4) 0.79
Delivery process block 6/22 (27.2) 8/29 (27.6) 1.00
Oxytocin use 32/182 (17.6) 28/163 (17.1) 1.00
Requirement of analgesia 92/182 (50.5) 75/163 (46.0) 0.92
Partus precipitatus 5/182 (2.7) 9/163 (5.5) 0.04
Data are mean ± SD (range) or number (percentage)
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reassuring fetal heart rate frequency in vaginal dinopros-
tone is obviously higher than OMS group (p = 0.04).
Discussion
Labor inductions have increased steadily over the past two
decades, meanwhile many methods have been tested, but
prostaglandins remain a preferred method for cervical
ripening and labor induction [5, 6]. In 2001, Hofmeyr [7]
compared the titrated oral misoprostol solution with vagi-
nal dinoprostone for labor induction, proposed the new
approach, titrated oral misoprostol solution administration
and was successful in minimizing the risk of uterine
hyperstimulation, and with no significant difference in
maternal adverse effect and neonatal outcome between the
two groups. From then on, many obstetricians pay attention
to titrated oral misoprostol induction method because of its
greater acceptance and fewer adverse effects. To further
evaluate safety and efficacy of titrate oral misoprostol
induction, many obstetricians compared with different
labor induction method. Comparing OMS with conven-
tional oxytocin induction, the result showed misoprostol
was a safe and effective drug with low complications for
the induction of labor, failure was seen less with miso-
prostol and cesarean sections are less frequently indicated
as compared to oxytocin [8–10]. Comparing OMS with
Foley catheter in cervical ripening and induction effect,
OMS group showed higher rate of delivery in 24 h, and in
labor augmentation, cesarean section and instrumental
delivery were somewhat fewer frequency than Foley group,
but these differences were not statistically significant, side
effects and neonatal complications were similar between
the two groups [11]. A comparative study about oral and
vaginal misoprostol for labor induction, which showed oral
misoprostol was as effective as vaginal misoprostol with
the advantage of shorter induction delivery interval, lower
cesarean section rate, and lower incidence of failed
Table 4 Maternal morbidity
Oral misoprostol (n = 212) Dinoprostone (n = 199) p value
Tachysystole 15/212 (7.0) 19/199 (9.5) 0.61
Hyperstimulation 5/212 (2.4) 18/199 (9.0) 0.03
Uterine hypertonus 5/212 (2.4) 16/199 (8.0) 0.03
Uterine rupture 0/212 0/199
membrane rupture 59/212 (27.8) 26/199 (13.1) 0.02
Tocolytics 6/212 (2.8) 17/199 (8.5) 0.04
Postpartum heamorrhage (ml) 14/212 (6.6) 15/199 (7.5) 0.73
C500 10/14 (71.4) 10/15 (66.7)
C1000 4/14 (28.6) 5/15 (33.3)
Intravenous antibiotics 32/212 (15.1) 35/199 (17.6) 0.96
Fever 2 0
Shivering 1 1
Nausea and vomiting 2 1
Data are number (percentage)
Table 5 Neonatal outcomes
Oral misoprostol (n = 212) Dinoprostone (n = 199) p value
Weight (g) 3020 ± 566.5 3110 ± 499.3 1.0
Non-reassuring fetal heart rate 15/212 (7.1) 22/199 (11.1) 0.04
Meconium-stained liquor 46/212 (21.7) 55/199 (27.6) 0.58
Apgar score
B7 at 1 min 8/212 (3.8) 9/199 (4.5) 0.66
B7 at 5 min 3/212 (1.4) 3/199 (1.5) 1.0
B7 at 10 min 0 1
NICU admission 15/212 (7.0) 15/199 (7.5) 1.0
Infant death 0 0
Data are number (percentage)
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induction rate, lower proportion of fetal distress and easy
intake [12, 13]. In 2011, WHO guideline also strongly
recommended oral misoprostol (25 lg, 2-hourly) than
vaginal low-dose misoprostol (25 lg, 6 hourly) for induc-
tion of labor. A randomized controlled trial about com-
parison of OMS with vaginal misoprostol showed that
OMS associated with a lower incidence of uterine hyper-
stimulation and a lower cesarean delivery rate than vaginal
misoprostol for labor induction in patients with unfavor-
able cervix [14]. A randomized double-blind trial com-
pared efficacy and safety about OMS and oral misoprostol,
participants were allocated to receive 20 ml of misoprostol
solution (1 lg/ml) orally every 1 h for four doses then
titrated to 40 lg every 1 h (OMS group) or 50 lg of
misoprostol orally every 4 h up to 12 h (oral group), and
concluded that oral misoprostol was as effective as titrated
misoprostol for cervical ripening and labor induction, but
had a lower incidence of tachysystole and a lower total
dose of misoprostol are required. Its results seem to be
contradictory to previous studies, perhaps OMS dose and
administration interval time difference could affect the
outcomes of induction of labor [15]. A systematic review
and net meta-analysis based on the data of Cochrane
Pregnancy and Childbirth Group’s Database of Trials show
low dose (\50 lg) titrated oral misoprostol solution had
the lowest probability of cesarean section, whereas vaginal
misprostol (C50 lg) had the highest probability of
achieving a vaginal delivery within 24 h [6].
However, up to now, there are still no definite conclu-
sions about the optimal dose, interval time and route of
administration. In our study, we take the new method that
gradually increase titrated oral misoprostol solution dose,
and adminstrate by 1–2 h, compare with vaginal dinopro-
tone for evaluating its effectiveness and safety. Evaluation
from mode and outcomes of delivery, which is similar for
total proportion of vaginal delivery between the two groups
during 48 h, nevertheless titrated oral misoprostol has the
property of relatively slower duration of labor compared
with dinoprostone, but accompanied the lower rate of
uterine hyperstimulation, hypertonus, usage frequency of
tocolytics and non-reassuring fetal heart; and concurrently
OMS with lower incidence of tachysystole, cesarean
delivery rate although with little significant difference in
our study. Analyzed from the respect of neonatal outcomes,
meconium-stained liquor rate in OMS group are lower than
vaginal dinoprostone. From these points of view, titrated
oral misoprostol is safer than dinoprostone for women
labor induction, these results are as same as other studies.
The incidence of non-reassuring fetal heart rate in
dinoprostone was significantly higher than OMS group, we
also found that the rate of fetal distress in dinoprotone was
also higher than OMS group, but the total proportion of
cesarean section between two group showed no difference
because of higher incidence of usage of tocolytics in
dinoprostone. Uterine tachysystole, hyperstimulation,
hypertonus accompanied non-reassuring fetal heart rate,
tocolytics should be used to at once, so that a part of
women would not been dealt with cesarean section. I think
that may be the reason of our study with higher non-reas-
suring fetal heart rate rather without higher incidence of
cesarean section in dinoprostone.
The phenomenon of higher proportion membrane rup-
ture in oral misoprostol perplexed us, and we exclude the
reason of amniotic membrane infection by placental
histopathology. This phenomenon was not reported in other
document literature, but 54 women in OMS group and 23
women in dinoprostone group presented on regular uterine
contraction and delivered within 12 h, and three women
did not present regular uterine contraction after 12 h, then
experienced oxytocin induction and delivered, two women
who presented delivery process block were transferred to
cesarean section. We thought that higher incidence of
membrane rupture in OMS group needed to be further
studied by expanded sample size.
Based on the cervix Bishop score, we found that with
the lower of cervix Bishop score, corresponding emergency
needed higher dose of oral misoprostol solution and longer
duration of time for labor induction. We consider that other
procedure of labor induction with OMS will be studied, for
women with lower Bishop score B3, could be adminis-
trated higher dose of initial dose, and increased more than
10 lg every time, and been longer than 2 h interval. Of
course, optimum dose and interval of administration for
women with low Bishop score need further extensive and
intensive study.
In conclusion, titrated oral misoprostol given hourly for
labor induction is as effective as vaginal dinoprostone from
the respect of maternal/fetal outcomes, but titrated oral
misoprostol is associated with lower rate of uterine
hyperstimulation, hypertonus, tachysystole, and nonreas-
suring fetal heart compared with vaginal dinoprostone.
Taking into account the higher vaginal delivery rate, lower
adverse effect for maternal/fetal outcomes, costs and
women’s preferences; our study consider that titrated oral
misoprostol solution would be a safe, cost-effective and
patient favorite way for inducing labor.
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